Gaisl Thomas, Rejmer Protazy, Thiel Sira, Haile Sarah R, Osswald Martin, Roos Malgorzata, Bloch Konrad E, Stradling John R, Kohler Malcolm
Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Both authors contributed equally.
Eur Respir J. 2020 Mar 20;55(3). doi: 10.1183/13993003.01526-2019. Print 2020 Mar.
Continuous positive airway pressure (CPAP) is currently the treatment of choice for sleepiness in patients with obstructive sleep apnoea (OSA); however, adherence is often thought to be suboptimal. We investigated the effects of suboptimal CPAP usage on objective and subjective sleepiness parameters in patients with OSA.
In this 2-week, parallel, double-blind, randomised controlled trial we enrolled moderate-to-severe OSA patients with excessive pre-treatment daytime sleepiness (Epworth sleepiness scale (ESS) score >10 points) who had suboptimal CPAP adherence over ≥12 months (mean nightly usage time 3-4 h). Patients were allocated through minimisation to either subtherapeutic CPAP ("sham CPAP") or continuation of CPAP ("therapeutic CPAP"). A Bayesian analysis with historical priors calculated the posterior probability of superiority.
Between May, 2016 and November, 2018, 57 patients (aged 60±8 years, 79% male, 93% Caucasian) were allocated in total, and 52 who completed the study (50% in each arm) were included in the final analysis. The unadjusted ESS score increase was 2.4 points (95% CI 0.6-4.2, p=0.01) in the sham-CPAP group when compared to continuing therapeutic CPAP. The probability of superiority of therapeutic CPAP over sham CPAP was 90.4% for ESS, 90.1% for systolic blood pressure and 80.3% for diastolic blood pressure.
Patients with moderate-to-severe OSA and daytime sleepiness are still getting a substantial benefit from suboptimal CPAP adherence, albeit not as much as they might get if they adhered more. Whether a similar statement can be made for even lower adherence levels remains to be established in future trials.
持续气道正压通气(CPAP)目前是阻塞性睡眠呼吸暂停(OSA)患者嗜睡症状的首选治疗方法;然而,人们通常认为其依从性欠佳。我们研究了CPAP使用不当对OSA患者客观和主观嗜睡参数的影响。
在这项为期2周的平行、双盲、随机对照试验中,我们纳入了中度至重度OSA患者,这些患者治疗前白天过度嗜睡(爱泼华嗜睡量表(ESS)评分>10分),且在≥12个月内CPAP依从性欠佳(平均每晚使用时间3 - 4小时)。通过最小化法将患者分为亚治疗性CPAP组(“假CPAP”)或继续使用CPAP组(“治疗性CPAP”)。采用带有历史先验的贝叶斯分析计算优越性的后验概率。
2016年5月至2018年11月期间,共分配了57例患者(年龄60±8岁,79%为男性,93%为白种人),最终分析纳入了52例完成研究的患者(每组各50%)。与继续使用治疗性CPAP相比,假CPAP组未调整的ESS评分增加了2.4分(95%CI 0.6 - 4.2,p = 0.01)。治疗性CPAP优于假CPAP的概率,ESS为90.4%,收缩压为90.1%,舒张压为80.3%。
中度至重度OSA且白天嗜睡的患者,尽管依从性欠佳,但仍能从CPAP治疗中获得显著益处,不过获益程度不如依从性更好时。对于更低的依从水平是否能得出类似结论,有待未来试验确定。